Clinical Diagnosis

Harvard researchers used data to shed light on pediatric neurotrophic keratopathy, revealing key insights into prevalence, vision outcomes, and treatment approaches.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

The year introduced shifts in residency education, and program directors reflect on changes, challenges, and what’s next.

Sezen Karakus, MD, highlights options including compounded cyclosporine, autologous serum drops, recombinant human nerve growth factor, and newer topical agents to manage refractory or neurotrophic dry eye.

Looking back on 2025, Neda Shamie shares how a challenging monocular patient reinforced the importance of patience, presence, and psychological support in ophthalmic care.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.

As artificial intelligence tools become more common in research, students must navigate issues including plagiarism, data consent, and equitable application.

Alternative management may avoid current concerns found with antibiotics.

A phase IV study in China found that 22 of 26 patients achieved complete healing of a persistent corneal epithelial defect or corneal ulcer after 8 weeks.

A study from a tertiary eye hospital suggests that effective keratitis management may have the potential to restore vision.

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of patient-centered eye care.

Second-year medical student Rishika Garg, from the University of Oklahoma College of Medicine in Oklahoma City, shares insights from a nationwide analysis revealing inconsistencies in ophthalmology residency leave policies.

Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma cases.

Ophthalmologists weigh in on evolving diagnostic tools, emerging therapies, and practical approaches for managing today’s most challenging ocular-surface cases.

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Surgeons reflect on milestones that have redefined patient care—and share a glimpse of the advances that promise to shape the next era of eye health.

Harpal Sandhu, MD, FRCSC, discusses the preclinical performance of XPK-640 and how Optigo’s hyaluronic acid-anchoring platform may reshape dosing expectations in retinal disease.

Tsu Shan Chambers shares how the film "My Eyes" uses authentic storytelling to raise awareness of inherited eye disease and the importance of preventive vision care.

Marking 5 decades of Ophthalmology Times, clinicians share the innovations that defined their training, shaped patient outcomes, and continue to push the field ahead.